Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research In Brief

This article was originally published in The Gray Sheet

Executive Summary

Conflict-of-interest disclosure: Editorial in Oct. 15 New England Journal of Medicine outlines new disclosure requirements for study authors, which will be adopted by all members of the International Committee of Medical Journal Editors. Under the new 1disclosure form, authors are asked to divulge four types of information: associations with commercial entities that provided support for the work reported in the submitted manuscript; associations with entities that could be viewed as having an interest in the general area of the submitted manuscript; similar financial associations involving spouses or children under 18 years old; and non-financial associations that may be relevant to the submitted manuscript. Because the new disclosure form has only been "use tested" by ICMJE member journals and may need adjustments, Oct. 15 to April 10, 2010, will be considered a beta-testing period, the editorial says

You may also be interested in...



Regulatory News In Brief

OIG work plan

Regulatory News In Brief

OIG work plan

BioMimetic Augment PMA Delayed Slightly As FDA Seeks Additional Data

FDA approval of BioMimetic Therapeutics' Augment synthetic bone graft will likely be delayed by several months after the agency recently requested 12-month follow-up data, the firm said

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT028065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel